ARTS-Diabetic Nephropathy (ARTS-DN) compared finerenone at different doses with placebo in 823 patients with type 2 diabetes, albuminuria (urinary albumin/creatinine ratio [UACR] ≥3.39 mg/mmol [30 mg/g]), eGFR >30 ml/min per 1.73 m2 and with a concomitant RAS blocker prior to screening. This evidence concerns the gene ALB and Arts syndrome.